Literature DB >> 20664258

Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study.

Florence Canouï-Poitrine1, Gerald Luc, Jean-Marie Bard, Jean Ferrieres, John Yarnell, Dominique Arveiler, Pierre Morange, Frank Kee, Alun Evans, Philippe Amouyel, Pierre Ducimetiere, Jean-Philippe Empana.   

Abstract

AIM: To compare within the same cohort the association of a large panel of lipids with the risk of incident coronary heart disease (CHD) and ischemic stroke events in participants of the Prospective Epidemiological Study of Myocardial Infarction.
METHODS: In this binational (Northern Ireland and France) prospective cohort, we considered 9,711 men aged 50-59 years free of CHD and stroke at baseline (1991-1993). The hazard ratios of each lipid marker for CHD and ischemic stroke events were estimated in separate Cox proportional hazard models adjusted for age, study center, systolic blood pressure, antihypertensive treatment, current smoking status, body mass index and diabetes.
RESULTS: After 10 years of follow-up, 635 men had a first CHD and 98 a first ischemic stroke event. Total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C, triglycerides, apolipoprotein (Apo) A1 and Apo B100, their ratios and lipoprotein (a) [Lp(a)] were all significantly predictive of future CHD. Associations with ischemic stroke followed the same trend as for CHD, but with lower strength, and none were statistically significant. However, none of the differences between the hazard ratios for CHD and for ischemic stroke were statistically significant.
CONCLUSIONS: In healthy, middle-aged men, total-C, HDL-C, LDL-C, non-HDL-C, triglycerides, Apo A1 and Apo B100, their ratios and Lp(a) are, if anything, weak predictors of ischemic stroke events over a 10-year period. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20664258     DOI: 10.1159/000319067

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  21 in total

Review 1.  Epidemiology and prevention of stroke: a worldwide perspective.

Authors:  Elena V Kuklina; Xin Tong; Mary G George; Pooja Bansil
Journal:  Expert Rev Neurother       Date:  2012-02       Impact factor: 4.618

2.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

3.  Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study.

Authors:  F Canouï-Poitrine; G Luc; Z Mallat; E Machez; A Bingham; J Ferrieres; J-B Ruidavets; M Montaye; J Yarnell; B Haas; D Arveiler; P Morange; F Kee; A Evans; P Amouyel; P Ducimetiere; J-P Empana
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

4.  Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review.

Authors:  Aladeen Alloubani; Refat Nimer; Rama Samara
Journal:  Curr Cardiol Rev       Date:  2021

5.  HDL (High-Density Lipoprotein) Subspecies, Prevalent Covert Brain Infarcts, and Incident Overt Ischemic Stroke: Cardiovascular Health Study.

Authors:  Manja Koch; Sarah A Aroner; Annette L Fitzpatrick; W T Longstreth; Jeremy D Furtado; Kenneth J Mukamal; Majken K Jensen
Journal:  Stroke       Date:  2021-10-14       Impact factor: 7.914

Review 6.  Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study.

Authors:  Hongli Dong; Wei Chen; Xiangyu Wang; Fuhua Pi; Yubin Wu; Shaojie Pang; Yuqing Xie; Fangfang Xia; Qingying Zhang
Journal:  Metab Brain Dis       Date:  2015-09-12       Impact factor: 3.584

7.  Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study.

Authors:  Chaoyang Li; Earl S Ford; James Tsai; Guixiang Zhao; Lina S Balluz; Samuel S Gidding
Journal:  Cardiovasc Diabetol       Date:  2011-05-23       Impact factor: 9.951

8.  Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study.

Authors:  Annick Alpérovitch; Tobias Kurth; Marion Bertrand; Marie-Laure Ancelin; Catherine Helmer; Stéphanie Debette; Christophe Tzourio
Journal:  BMJ       Date:  2015-05-19

9.  Biomarker discovery in serum from patients with carotid atherosclerosis.

Authors:  Thomas J Degraba; Gerard T Hoehn; Paul A Nyquist; Honghui Wang; Ray Kenney; Denise A Gonzales; Steven J Kern; Sai-Xia Ying; Peter J Munson; Anthony F Suffredini
Journal:  Cerebrovasc Dis Extra       Date:  2011-12-03

10.  The effects of cranberry juice on serum glucose, apoB, apoA-I, Lp(a), and Paraoxonase-1 activity in type 2 diabetic male patients.

Authors:  Farzad Shidfar; Iraj Heydari; Seyed Javed Hajimiresmaiel; Sharieh Hosseini; Shahrzad Shidfar; Fariba Amiri
Journal:  J Res Med Sci       Date:  2012-04       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.